WO2000019824A1 - Novel treatment for stroke management - Google Patents
Novel treatment for stroke management Download PDFInfo
- Publication number
- WO2000019824A1 WO2000019824A1 PCT/US1999/023274 US9923274W WO0019824A1 WO 2000019824 A1 WO2000019824 A1 WO 2000019824A1 US 9923274 W US9923274 W US 9923274W WO 0019824 A1 WO0019824 A1 WO 0019824A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- injury
- tnf
- cytokine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention relates to the novel use of imidazole compounds in the treatment of stroke and stroke management.
- Interleukin-1 IL-1
- Tumor Necrosis Factor TNF
- IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)].
- the myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.
- TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, reperfusion injury, graft vs.
- allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
- AIDS cachexia secondary to infection or malignancy
- cachexia secondary to acquired immune deficiency syndrome
- AIDS AIDS
- ARC AIDS related complex
- keloid formation scar tissue formation
- Crohn's disease Crohn's disease
- ulcerative colitis or pyresis.
- Interleukin-8 is a chemotactic factor first identified and characterized in 1987.
- IL-8 is produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Its production from endothelial cells is induced by IL-1, TNF, or lipopolysachharide (LPS).
- Human IL-8 has been shown to act on Mouse, Guinea Pig, Rat, and Rabbit Neutrophils. Many different names have been applied to IL-8, such as neutrophil attractant/activation protein- 1 (NAP-1), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor.
- NAP-1 neutrophil attractant/activation protein- 1
- MDNCF monocyte derived neutrophil chemotactic factor
- NAF neutrophil activating factor
- T-cell lymphocyte chemotactic factor T-cell lymphocyte chemotactic factor.
- IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysozomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis, this may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases are characterized by massive neutrophil infiltration.
- IL-1 and TNF affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
- This invention relates to the use of substituted imidazole compounds, or pharmaceutical compositions thereof in the treatment of stroke, and stroke management.
- the compounds for use herein are described in PCT US97/09888 filed 6 June 1997, and published 18 December 1997 as WO 97/47618, Liverton et al., now US Patent 5,859,041 granted January 12, 1999, whose disclosures are incorporated herein by reference in their entirety.
- the present invention is to the novel use of the compounds described in WO 97/47618 for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 98/47899 (PCT/US98/07831), Dodd et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 98/47892 (PCT US98/07910), Beers et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 99/01449 (PCT/EP98/03930), Revesz et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries.
- Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 98/52941 (PCT/US98/11684), Hanson et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries.
- Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 97/05878 (PCT/US96/12922), De Laszlo et al., now US Patent
- Another aspect of the present invention relates to the novel use of compounds described in WO 97/16441 (PCT/US96/17324), De Laszlo et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 98/21957 (PCT/US97/21019), Chang et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries.
- Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 97/12876 (PCT/US96/15880), now US Patent 5,717, 100, granted February 10, 1998, Selnick et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 97/16426 (PCT/US 96/ 17477), De Laszlo et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 97/05877 (PCT/US96/12917), De Laszlo et al., now US Patent 5,782,778, granted August 1 1, 1998, for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 97/16442 (PCT/US96/18539), De Laszlo et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries. Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- Another aspect of the present invention relates to the novel use of compounds described in WO 98/52940 (PCT/US98/10436), Anantanarayan et al., for the treatment, an acute setting, as well as including prophylactic use, in preventing in those individuals deemed susceptible to, various CNS injuries.
- Synthetic chemistry, dosages, and methods of making pharmaceutical formulations thereof are also contained within the noted patent application.
- CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region. Also included within this definition is ischemic stroke, particularly to the brain area.
- Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel.
- the role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.
- CSBP cytokine suppressive binding protein activity
- TNF- is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression.
- Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu et al., Stoke, Vol. 25., No. 7, pp. 1481-88 (1994) whose disclosure is incorporated herein by reference.
- CSBP cytokine specific binding protein
- WO 95/07922 whose disclosure is incorporated by reference in its entirety, as well as in US Paten 5,777,097.
- a kinase binding assay is also described herein. Updated versions of a CSBP kinase assay may be found in later filed SB patent applications including WO 98/57966 for instance.
- the compounds of WO 97/47618 can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by a neurotraumatic event, such as closed head injuries.
- the compounds of WO 99/20624, WO 98/52940, WO 97/16442, WO 97/05877, WO 97/16426, WO 97/12876, WO 98/21957, WO 97/16441, WO 97/05878, WO 98/52941, WO 99/01449, WO 98/47892, WO 99/03837, WO 98/52937, and WO 98/47899 can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by a neurotraumatic event, such as closed head injuries.
- the compounds of these patent applications are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF and are therefore of use in therapy.
- IL-1, IL-6, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions.
- the inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
- the present invention provides for a method of treating a neurotraumatic disease, in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a CSALDTM, cytokine suppressive inhibitory compound, wherein the compound is an inhibitor of the CSBP/p38/RK kinase.
- the term "inhibiting the production of IL-1 (IL-6, IL-8 or TNF)” refers to: a) a decrease of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels by inhibition of the in vivo release of the cytokine by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the genomic level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels; c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL-1, IL-6, IL-8 or TNF) as a postranslational event; or d) a down regulation, at the translational level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in
- cytokine interfering or "cytokine suppressive amount” refers to an effective amount of a compound of Formula (I) which will cause a decrease in the in vivo levels of the cytokine to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production.
- CSBP MAP kinase family
- RK MAP kinase
- Activation of this novel protein kinase via dual phosphorylation has been observed in different cell systems upon stimulation by a wide spectrum of stimuli, such as physicochemical stress and treatment with lipopolysaccharide or proinflammatory cytokines such as interleukin-1 and tumor necrosis factor
- the cytokine biosynthesis inhibitors, of the present invention, compounds of Formula (I) have been determined to be potent and selective inhibitors of CSBP/p38/RK kinase activity These inhibitors are of aid in determining the signaling pathways involvement in inflammatory responses
- mice and rats are injected with LPS.
- mice Male Balb/c mice from Charles River Laboratories are pretreated (30 minutes) with compound or vehicle After the 30 min pretreat time, the mice are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co , St Louis, MO) 25 ug/mouse in 25 ul phosphate buffered saline (pH 7 0) intraperitoneally Two hours later the mice are killed by CO2 inhalation and blood samples are collected by exsanguination into heparinized blood collection tubes and stored on ice The blood samples are centrifuged and the plasma collected and stored at -20°C until assayed for TNF ⁇ by ELISA
- mice Male Lewis rats from Charles River Laboratories are pretreated at various times with compound or vehicle After a determined pretreat time, the rats are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co , St Louis, MO) 3 0 mg/kg intraperitoneally The rats are killed by CO2 inhalation and heparinized whole blood is collected from each rat by cardiac puncture 90 minutes after the LPS injection. The blood samples are centrifuged and the plasma collected for analysis by ELISA for TNF ⁇ levels.
- LPS lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co , St Louis, MO
- TNF ⁇ levels are measured using a sandwich ELISA, as described in Olivera et al., Circ. Shock, 37, 301-306, (1992), whose disclosure is incorporated by reference in its entirety herein, using a hamster monoclonal antimurine TNF ⁇ (Genzyme, Boston, MA) as the capture antibody and a polyclonal rabbit antimurine TNFa (Genzyme) as the second antibody.
- a peroxidase-conjugated goat antirabbit antibody Pierce, Rockford, IL
- TNF ⁇ levels in the plasma samples from each animal are calculated from a standard curve generated with recombinant murine TNF ⁇ (Genzyme).
- Test compound concentrations are prepared at 10 X concentrations and LPS prepared at 1 ug/ml (final cone, of 50 ng/ml LPS) and added in 50 uL volumes to 1.5 mL eppendorf tubes.
- Heparinized human whole blood is obtained from healthy volunteers and is dispensed into eppendorf tubes containing compounds and LPS in 0.4 mL volumes and the tubes incubated at 37 C. Following a 4 hour incubation, the tubes are centrifuged at 5000 rpm for 5 minutes in a TOMY microfuge, plasma is withdrawn and frozen at -80 C.
- Cytokine measurement IL-I and/or TNF were quantified using a standardized ELISA technology. An in-house ELISA kit was used to detect human IL-1 and TNF. Concentrations of IL-1 or TNF were determined from standard curves of the appropriate cytokine and IC50 values for test compound (concentration that inhibited 50% of LPS-stimulated cytokine production) were calculated by linear regression analysis.
- This assay measures the CSBP/p38-catalyzed transfer of ⁇ 2p from [a- ⁇ 2p]ATP to threonine residue in an epidermal growth factor receptor (EGFR)-derived peptide (T669) with the following sequence: KRELVEPL7PSGEAPNQALLR (residues 661- 681). (See Gallagher et al, "Regulation of Stress Induced Cytokine Production by Pyridinyl Imidazoles: Inhibition of CSBP Kinase", BioOrganic & Medicinal Chemistry, 1997, 5, 49-64).
- Reactions are carried in round bottom 96 well plate (from Corning) in a 30 ml volume. Reactions contained (in final concentration): 25 mM Hepes, pH 7.5; 8 mM MgCl 2 ; 0.17 mM ATP (the Kmr ATP ] of p38 (see Lee et al., Nature 300, n72 pg.
- Reactions are terminated by adding 10 ul of 0.3 M phosphoric acid, and phosphorylated peptide is isolated from the reactions by capturing it on p81 phosphocellulose filters. Filters are washed with 75 mM phosphoric acids, and incorporated 32P was quantified using beta scintillation counter. Under these conditions, the specific activity of p38 is about 400-450 pmol/pmol enzyme, and the activity linear for up to 2 hr of incubation. The kinase activity values are obtained after subtracting values generated in the absence of substrate which are 10-15% of total values.
- This assay describes a method for determining the inhibitory effects of compounds of Formula (I) on human PGHS-2 protein expression in LPS stimulated human monocytes.
- a suitable assay for PGHS-2 protein expression may be found in a number of publications, including US Patent 5,593,992 whose disclosure is incorporated herein by reference.
- This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- ⁇ is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- ⁇ plays an important role in both the acute and regenerative response to CNS trauma.
- a suitable assay may be found in WO 97/35856 whose disclosure is incorporated herein by reference.
- This assay characterizes the regional expression of interleukin-l ⁇ (IL-l ⁇ ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-l ⁇ mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-l ⁇ play a role in the post- traumatic pathologic or regenerative sequelae of brain injury.
- TBI lateral fluid-percussion traumatic brain injury
- Suitable candidate compound is administered by either intravenous, or oral administration. Pose 24 hours of MCAO, the neurological deficits and stained forebrain sections are evaluated. Suitable endpoints are 1) neurological deficits in the forelimb, and hindlimb; 2) infact volume of (mm3); and hemispheric infarct (%; normalized to normal contralateral hemisphere).
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002346665A CA2346665A1 (en) | 1998-10-07 | 1999-10-06 | Novel treatment for stroke management |
JP2000573195A JP2002526388A (en) | 1998-10-07 | 1999-10-06 | Novel measures to manage seizures |
US09/806,289 US6649617B1 (en) | 1998-10-07 | 1999-10-06 | Treatment for stroke management |
EP99953074A EP1119254A4 (en) | 1998-10-07 | 1999-10-06 | Novel treatment for stroke management |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10332098P | 1998-10-07 | 1998-10-07 | |
US60/103,320 | 1998-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000019824A1 true WO2000019824A1 (en) | 2000-04-13 |
Family
ID=22294555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/023274 WO2000019824A1 (en) | 1998-10-07 | 1999-10-06 | Novel treatment for stroke management |
Country Status (5)
Country | Link |
---|---|
US (1) | US6649617B1 (en) |
EP (1) | EP1119254A4 (en) |
JP (1) | JP2002526388A (en) |
CA (1) | CA2346665A1 (en) |
WO (1) | WO2000019824A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599910B1 (en) | 1998-08-20 | 2003-07-29 | Smithkline Beecham Corporation | Substituted triazole compounds |
EP1676574A2 (en) | 2004-12-30 | 2006-07-05 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
US7268139B2 (en) | 2002-08-29 | 2007-09-11 | Scios, Inc. | Methods of promoting osteogenesis |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US7427420B2 (en) | 2000-03-07 | 2008-09-23 | Fuji Oil Company, Limited | Process for producing confectionery highly stable to heat |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11291659B2 (en) | 2017-10-05 | 2022-04-05 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
US5792778A (en) * | 1995-08-10 | 1998-08-11 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0871444A4 (en) | 1995-08-10 | 1999-01-13 | Merck & Co Inc | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
JP3294616B2 (en) | 1995-08-10 | 2002-06-24 | メルク エンド カンパニー インコーポレーテッド | 2-Substituted arylpyrroles, compositions containing such compounds and methods of use |
IL123950A (en) | 1995-10-06 | 2001-04-30 | Merck & Co Inc | Substituted imidazoles having anti-cancer and cytokine inhibitory activity and pharmaceutical compositions containing them |
WO1997016426A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
WO1997016442A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
WO1997016441A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
JP2000507558A (en) | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Novel treatment for CNS injury |
US6235760B1 (en) | 1996-03-25 | 2001-05-22 | Smithkline Beecham Corporation | Treatment for CNS injuries |
WO1997047618A1 (en) | 1996-06-10 | 1997-12-18 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
JP2001506230A (en) * | 1996-08-09 | 2001-05-15 | スミスクライン・ビーチャム・コーポレイション | New piperazine-containing compounds |
WO1998007425A1 (en) * | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
WO1998021957A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
ZA9711092B (en) * | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
WO1998047899A1 (en) | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
UA65572C2 (en) | 1997-04-24 | 2004-04-15 | Ortho Mcneil Pharm Inc | Substituted imidazoles, intermediate compounds for the preparation thereof, a method for the preparation of substituted imidazoles and a method for the treatment of inflammatory diseases |
EA003925B1 (en) | 1997-05-22 | 2003-10-30 | Дж.Д.Сирл Энд Ко | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
WO1998052937A2 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
JP2002504909A (en) * | 1997-06-13 | 2002-02-12 | スミスクライン・ビーチャム・コーポレイション | New substituted pyrazole and pyrazoline compounds |
EP0994870A4 (en) * | 1997-06-19 | 2002-10-23 | Smithkline Beecham | Novel aryloxy substituted pyrimidine imidazole compounds |
US6040320A (en) | 1997-06-30 | 2000-03-21 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
TW517055B (en) * | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
PL340412A1 (en) | 1997-10-20 | 2001-01-29 | Hoffmann La Roche | Bicyclic kinase inhibitors |
-
1999
- 1999-10-06 CA CA002346665A patent/CA2346665A1/en not_active Abandoned
- 1999-10-06 JP JP2000573195A patent/JP2002526388A/en not_active Withdrawn
- 1999-10-06 US US09/806,289 patent/US6649617B1/en not_active Expired - Fee Related
- 1999-10-06 WO PCT/US1999/023274 patent/WO2000019824A1/en not_active Application Discontinuation
- 1999-10-06 EP EP99953074A patent/EP1119254A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792778A (en) * | 1995-08-10 | 1998-08-11 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
Non-Patent Citations (1)
Title |
---|
See also references of EP1119254A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6599910B1 (en) | 1998-08-20 | 2003-07-29 | Smithkline Beecham Corporation | Substituted triazole compounds |
US7427420B2 (en) | 2000-03-07 | 2008-09-23 | Fuji Oil Company, Limited | Process for producing confectionery highly stable to heat |
US7268139B2 (en) | 2002-08-29 | 2007-09-11 | Scios, Inc. | Methods of promoting osteogenesis |
US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
EP1676574A2 (en) | 2004-12-30 | 2006-07-05 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10537560B2 (en) | 2017-10-05 | 2020-01-21 | Fulcrum Therapeutics. Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11291659B2 (en) | 2017-10-05 | 2022-04-05 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11479770B2 (en) | 2017-10-05 | 2022-10-25 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
Also Published As
Publication number | Publication date |
---|---|
JP2002526388A (en) | 2002-08-20 |
EP1119254A1 (en) | 2001-08-01 |
US6649617B1 (en) | 2003-11-18 |
EP1119254A4 (en) | 2004-05-12 |
CA2346665A1 (en) | 2000-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6096739A (en) | Treatment for CNS injuries | |
US6774127B2 (en) | Pyrazole and pyrazoline substituted compounds | |
US6362193B1 (en) | Cycloalkenyl substituted compounds | |
EP0961618B1 (en) | 5-Pyrimidinyl-4-yl-Imidazole Derivate zur Behandlung von CSBP/RK/p38 vermittelten Erkrankungen | |
US6528512B1 (en) | Pyrimidine compounds useful in treating cytokine mediated diseases | |
US20050054614A1 (en) | Methods of inhibiting leukocyte accumulation | |
US20100029693A1 (en) | Novel pi3k delta inhibitors and methods of use thereof | |
EP0889887A1 (en) | Novel treatment for cns injuries | |
CA2316296A1 (en) | Use of csaidtm compounds for the management of uterine contractions | |
US6861417B2 (en) | Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines | |
MXPA01002175A (en) | Quinazoline derivatives as medicaments. | |
US6649617B1 (en) | Treatment for stroke management | |
US8604045B2 (en) | Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis | |
CN108794484B (en) | [1,2,4] triazolo [4,3-a ] pyrazine derivative, pharmaceutical composition, preparation method and application thereof | |
EP0994870A1 (en) | Novel aryloxy substituted pyrimidine imidazole compounds | |
EP3353154B1 (en) | 3-hydroxy-7-(sulfonyl)quinazoline-2,4(1h,3h)-dione and 3-hydroxy-pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives and related compounds as flap-endonuclease 1 (fen-1) inhibitors for use in cancer therapy | |
US6369068B1 (en) | Amino substituted pyrimidine containing compounds | |
Tamura et al. | Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist | |
Mitchell et al. | Protein kinase regulation of tumor necrosis factor alpha stimulated collagenase and stromelysin message levels in chondrocytes | |
JP2023548190A (en) | Pharmaceutical compositions comprising FLT3 inhibitors for the treatment of myeloid leukemia | |
JPWO2003047625A1 (en) | Neurotransmitter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09806289 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2346665 Country of ref document: CA Ref country code: JP Ref document number: 2000 573195 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2346665 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999953074 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999953074 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999953074 Country of ref document: EP |